Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
Age
40–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Patients with COPD who completed the treatment period in a previous itepekimab COPD Phase 3 clinical study (ie, EFC16750 or EFC16819) and for which an end-of-treatment (EOT) visit occurred no later than 3 days before the enrolment visit of this study.
You may not be if
Diagnosis of a malignancy during parent study, except a squamous or basal cell carcinoma of the skin
Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an immunocompromised status
Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study
Any situation that led to a permanent premature IMP discontinuation in parent trials
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
